These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1451 related items for PubMed ID: 25359382

  • 1. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of methotrexate with step-down glucocorticoid remission induction (COBRA Slim) versus other intensive treatment strategies for early rheumatoid arthritis in a treat-to-target approach: 1-year results of CareRA, a randomised pragmatic open-label superiority trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Meyfroidt S, Van der Elst K, Westhovens R.
    Ann Rheum Dis; 2017 Mar; 76(3):511-520. PubMed ID: 27432356
    [Abstract] [Full Text] [Related]

  • 3. Patients lacking classical poor prognostic markers might also benefit from a step-down glucocorticoid bridging scheme in early rheumatoid arthritis: week 16 results from the randomized multicenter CareRA trial.
    Verschueren P, De Cock D, Corluy L, Joos R, Langenaken C, Taelman V, Raeman F, Ravelingien I, Vandevyvere K, Lenaerts J, Geens E, Geusens P, Vanhoof J, Durnez A, Remans J, Vander Cruyssen B, Van Essche E, Sileghem A, De Brabanter G, Joly J, Van der Elst K, Meyfroidt S, Westhovens R, CareRA study group.
    Arthritis Res Ther; 2015 Apr 09; 17(1):97. PubMed ID: 25889222
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness of different combinations of DMARDs and glucocorticoid bridging in early rheumatoid arthritis: two-year results of CareRA.
    Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Verschueren P, CareRA study group.
    Rheumatology (Oxford); 2019 Dec 01; 58(12):2284-2294. PubMed ID: 31236568
    [Abstract] [Full Text] [Related]

  • 5. Two-year cost-effectiveness of different COBRA-like intensive remission induction schemes in early rheumatoid arthritis: a piggyback study on the pragmatic randomised controlled CareRA trial.
    Pazmino S, Boonen A, Stouten V, De Cock D, Joly J, Van der Elst K, Westhovens R, Verschueren P.
    Ann Rheum Dis; 2020 May 01; 79(5):556-565. PubMed ID: 32241795
    [Abstract] [Full Text] [Related]

  • 6. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
    Heimans L, Wevers-de Boer KV, Visser K, Goekoop RJ, van Oosterhout M, Harbers JB, Bijkerk C, Speyer I, de Buck MP, de Sonnaville PB, Grillet BA, Huizinga TW, Allaart CF.
    Ann Rheum Dis; 2014 Jul 01; 73(7):1356-61. PubMed ID: 23716067
    [Abstract] [Full Text] [Related]

  • 7. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2014 Apr 01; 73(4):654-61. PubMed ID: 23434570
    [Abstract] [Full Text] [Related]

  • 8. Five-year treat-to-target outcomes after methotrexate induction therapy with or without other csDMARDs and temporary glucocorticoids for rheumatoid arthritis in the CareRA trial.
    Stouten V, Westhovens R, Pazmino S, De Cock D, Van der Elst K, Joly J, Bertrand D, Verschueren P.
    Ann Rheum Dis; 2021 Aug 01; 80(8):965-973. PubMed ID: 33811036
    [Abstract] [Full Text] [Related]

  • 9. Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use.
    Proudman SM, James MJ, Spargo LD, Metcalf RG, Sullivan TR, Rischmueller M, Flabouris K, Wechalekar MD, Lee AT, Cleland LG.
    Ann Rheum Dis; 2015 Jan 01; 74(1):89-95. PubMed ID: 24081439
    [Abstract] [Full Text] [Related]

  • 10. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study.
    Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA, FARR study group.
    Clin Exp Rheumatol; 2006 Jan 01; 24(6 Suppl 43):S-77-82. PubMed ID: 17083767
    [Abstract] [Full Text] [Related]

  • 11. Intensive combination treatment regimens, including prednisolone, are effective in treating patients with early rheumatoid arthritis regardless of additional etanercept: 1-year results of the COBRA-light open-label, randomised, non-inferiority trial.
    ter Wee MM, den Uyl D, Boers M, Kerstens P, Nurmohamed M, van Schaardenburg D, Voskuyl AE, Lems WF.
    Ann Rheum Dis; 2015 Jun 01; 74(6):1233-40. PubMed ID: 24818633
    [Abstract] [Full Text] [Related]

  • 12. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 01; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 13. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D.
    Ann Rheum Dis; 2007 Aug 01; 66(8):1059-65. PubMed ID: 17307765
    [Abstract] [Full Text] [Related]

  • 14. Short-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritis.
    Fleischmann R, Koenig AS, Szumski A, Nab HW, Marshall L, Bananis E.
    Rheumatology (Oxford); 2014 Nov 01; 53(11):1984-93. PubMed ID: 24907147
    [Abstract] [Full Text] [Related]

  • 15. Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial.
    Bakker MF, Jacobs JW, Welsing PM, Verstappen SM, Tekstra J, Ton E, Geurts MA, van der Werf JH, van Albada-Kuipers GA, Jahangier-de Veen ZN, van der Veen MJ, Verhoef CM, Lafeber FP, Bijlsma JW, Utrecht Rheumatoid Arthritis Cohort Study Group.
    Ann Intern Med; 2012 Mar 06; 156(5):329-39. PubMed ID: 22393128
    [Abstract] [Full Text] [Related]

  • 16. Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.
    de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE.
    Ann Rheum Dis; 2014 Jul 06; 73(7):1331-9. PubMed ID: 24788619
    [Abstract] [Full Text] [Related]

  • 17. Three out of four disease-modifying anti-rheumatic drug-naïve rheumatoid arthritis patients meet 28-joint Disease Activity Score remission at 12 months: results from the FIN-ERA cohort.
    Rannio T, Asikainen J, Hannonen P, Yli-Kerttula T, Ekman P, Pirilä L, Kuusalo L, Mali M, Puurtinen-Vilkki M, Kortelainen S, Paltta J, Taimen K, Kauppi M, Laiho K, Nyrhinen S, Mäkinen H, Isomäki P, Uotila T, Aaltonen K, Kautiainen H, Sokka T.
    Scand J Rheumatol; 2017 Nov 06; 46(6):425-431. PubMed ID: 28367663
    [Abstract] [Full Text] [Related]

  • 18. Clinical and radiographic outcome of a treat-to-target strategy using methotrexate and intra-articular glucocorticoids with or without adalimumab induction: a 2-year investigator-initiated, double-blinded, randomised, controlled trial (OPERA).
    Hørslev-Petersen K, Hetland ML, Ørnbjerg LM, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Lottenburger T, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2016 Sep 06; 75(9):1645-53. PubMed ID: 26489704
    [Abstract] [Full Text] [Related]

  • 19. Optimal use of non-biologic therapy in the treatment of rheumatoid arthritis.
    Jacobs JW.
    Rheumatology (Oxford); 2012 Jun 06; 51 Suppl 4():iv3-8. PubMed ID: 22513146
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: results from the double-blind placebo-controlled MASCOT study.
    Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA, Steven M, Zoma A, Morrison E, Sambrook M, Wui Poon F, Hampson R, McDonald F, Tierney A, Henderson N, Ford I.
    Ann Rheum Dis; 2007 Feb 06; 66(2):235-41. PubMed ID: 16926184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.